Dr. West Discusses Crizotinib in ALK-NSCLC Trial Results

Video

Dr. Jack West from the Swedish Cancer Institute Discusses Crizotinib in ALK-NSCLC Trial Results

H. Jack West, MD, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington discusses crizotinib (Xalkori) in ALK-non-small cell lung cancer (NSCLC) trial results. He describes that the information presented at ASCO, both in 2011 and in 2010, only improved with time and as the test population got larger.

The FDA approved crizotinib August 26, 2011.

Related Videos
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD
Daniel Olson, MD
Nan Chen, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Akriti Jain, MD
Samer A. Srour, MB ChB, MS
Related Content
FDA

FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC

April 18th 2024
Article
Hari B. Keshava, MD

Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection

October 23rd 2023
Podcast
James Chih-Hsin Yang, MD, PhD, National Taiwan University Hospital, National Taiwan University Cancer Centre

Savolitinib/Osimertinib Yields Responses in EGFR-Mutant, MET-Amplified, Osimertinib-Resistant NSCLC

April 10th 2024
Article
Adnan F. Danish, MD

Danish Discusses the Benefits of SCINTIX Biology-Guided Radiotherapy in Metastatic Lung and Bone Cancers

August 7th 2023
Podcast
FDA

FDA Grants Breakthrough Therapy Designation to First-Line Sunvozertinib for EGFR Exon 20+ NSCLC

April 8th 2024
Article
Suresh Senan, PhD

Consolidation Durvalumab Generates Survival Benefit in LS-SCLC

April 5th 2024
Article